Global Hereditary Angioedema Drug Supply, Demand and Key Producers, 2023-2029

Page: 104

Published Date: 26 Aug 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Hereditary Angioedema Drug market size is expected to reach $ 1188.6 million by 2029, rising at a market growth of 6.5% CAGR during the forecast period (2023-2029).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.

This report studies the global Hereditary Angioedema Drug production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Hereditary Angioedema Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hereditary Angioedema Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Hereditary Angioedema Drug total production and demand, 2018-2029, (K Units)
Global Hereditary Angioedema Drug total production value, 2018-2029, (USD Million)
Global Hereditary Angioedema Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Hereditary Angioedema Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Hereditary Angioedema Drug domestic production, consumption, key domestic manufacturers and share
Global Hereditary Angioedema Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Hereditary Angioedema Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Hereditary Angioedema Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Hereditary Angioedema Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pharming Group NV, Takeda, CSL Limited, IBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hereditary Angioedema Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Hereditary Angioedema Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Hereditary Angioedema Drug Market, Segmentation by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Global Hereditary Angioedema Drug Market, Segmentation by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Companies Profiled:
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.

Key Questions Answered
1. How big is the global Hereditary Angioedema Drug market?
2. What is the demand of the global Hereditary Angioedema Drug market?
3. What is the year over year growth of the global Hereditary Angioedema Drug market?
4. What is the production and production value of the global Hereditary Angioedema Drug market?
5. Who are the key producers in the global Hereditary Angioedema Drug market?

Table of Contents

1 Supply Summary
    1.1 Hereditary Angioedema Drug Introduction
    1.2 World Hereditary Angioedema Drug Supply & Forecast
        1.2.1 World Hereditary Angioedema Drug Production Value (2018 & 2022 & 2029)
        1.2.2 World Hereditary Angioedema Drug Production (2018-2029)
        1.2.3 World Hereditary Angioedema Drug Pricing Trends (2018-2029)
    1.3 World Hereditary Angioedema Drug Production by Region (Based on Production Site)
        1.3.1 World Hereditary Angioedema Drug Production Value by Region (2018-2029)
        1.3.2 World Hereditary Angioedema Drug Production by Region (2018-2029)
        1.3.3 World Hereditary Angioedema Drug Average Price by Region (2018-2029)
        1.3.4 North America Hereditary Angioedema Drug Production (2018-2029)
        1.3.5 Europe Hereditary Angioedema Drug Production (2018-2029)
        1.3.6 China Hereditary Angioedema Drug Production (2018-2029)
        1.3.7 Japan Hereditary Angioedema Drug Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Hereditary Angioedema Drug Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Hereditary Angioedema Drug Major Market Trends

2 Demand Summary
    2.1 World Hereditary Angioedema Drug Demand (2018-2029)
    2.2 World Hereditary Angioedema Drug Consumption by Region
        2.2.1 World Hereditary Angioedema Drug Consumption by Region (2018-2023)
        2.2.2 World Hereditary Angioedema Drug Consumption Forecast by Region (2024-2029)
    2.3 United States Hereditary Angioedema Drug Consumption (2018-2029)
    2.4 China Hereditary Angioedema Drug Consumption (2018-2029)
    2.5 Europe Hereditary Angioedema Drug Consumption (2018-2029)
    2.6 Japan Hereditary Angioedema Drug Consumption (2018-2029)
    2.7 South Korea Hereditary Angioedema Drug Consumption (2018-2029)
    2.8 ASEAN Hereditary Angioedema Drug Consumption (2018-2029)
    2.9 India Hereditary Angioedema Drug Consumption (2018-2029)

3 World Hereditary Angioedema Drug Manufacturers Competitive Analysis
    3.1 World Hereditary Angioedema Drug Production Value by Manufacturer (2018-2023)
    3.2 World Hereditary Angioedema Drug Production by Manufacturer (2018-2023)
    3.3 World Hereditary Angioedema Drug Average Price by Manufacturer (2018-2023)
    3.4 Hereditary Angioedema Drug Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Hereditary Angioedema Drug Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Hereditary Angioedema Drug in 2022
        3.5.3 Global Concentration Ratios (CR8) for Hereditary Angioedema Drug in 2022
    3.6 Hereditary Angioedema Drug Market: Overall Company Footprint Analysis
        3.6.1 Hereditary Angioedema Drug Market: Region Footprint
        3.6.2 Hereditary Angioedema Drug Market: Company Product Type Footprint
        3.6.3 Hereditary Angioedema Drug Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Hereditary Angioedema Drug Production Value Comparison
        4.1.1 United States VS China: Hereditary Angioedema Drug Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Hereditary Angioedema Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Hereditary Angioedema Drug Production Comparison
        4.2.1 United States VS China: Hereditary Angioedema Drug Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Hereditary Angioedema Drug Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Hereditary Angioedema Drug Consumption Comparison
        4.3.1 United States VS China: Hereditary Angioedema Drug Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Hereditary Angioedema Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Hereditary Angioedema Drug Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Hereditary Angioedema Drug Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Hereditary Angioedema Drug Production (2018-2023)
    4.5 China Based Hereditary Angioedema Drug Manufacturers and Market Share
        4.5.1 China Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Hereditary Angioedema Drug Production Value (2018-2023)
        4.5.3 China Based Manufacturers Hereditary Angioedema Drug Production (2018-2023)
    4.6 Rest of World Based Hereditary Angioedema Drug Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Hereditary Angioedema Drug Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Hereditary Angioedema Drug Production (2018-2023)

5 Market Analysis by Type
    5.1 World Hereditary Angioedema Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 C1 Esterase Inhibitor
        5.2.2 Kallikrein Inhibitor
        5.2.3 Selective Bradykinin B2 Receptor Antagonist
    5.3 Market Segment by Type
        5.3.1 World Hereditary Angioedema Drug Production by Type (2018-2029)
        5.3.2 World Hereditary Angioedema Drug Production Value by Type (2018-2029)
        5.3.3 World Hereditary Angioedema Drug Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Hereditary Angioedema Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Retail Pharmacies
        6.2.2 Hospital Pharmacies
        6.2.3 Online Pharmacies
    6.3 Market Segment by Application
        6.3.1 World Hereditary Angioedema Drug Production by Application (2018-2029)
        6.3.2 World Hereditary Angioedema Drug Production Value by Application (2018-2029)
        6.3.3 World Hereditary Angioedema Drug Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Pharming Group NV
        7.1.1 Pharming Group NV Details
        7.1.2 Pharming Group NV Major Business
        7.1.3 Pharming Group NV Hereditary Angioedema Drug Product and Services
        7.1.4 Pharming Group NV Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Pharming Group NV Recent Developments/Updates
        7.1.6 Pharming Group NV Competitive Strengths & Weaknesses
    7.2 Takeda
        7.2.1 Takeda Details
        7.2.2 Takeda Major Business
        7.2.3 Takeda Hereditary Angioedema Drug Product and Services
        7.2.4 Takeda Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Takeda Recent Developments/Updates
        7.2.6 Takeda Competitive Strengths & Weaknesses
    7.3 CSL Limited
        7.3.1 CSL Limited Details
        7.3.2 CSL Limited Major Business
        7.3.3 CSL Limited Hereditary Angioedema Drug Product and Services
        7.3.4 CSL Limited Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 CSL Limited Recent Developments/Updates
        7.3.6 CSL Limited Competitive Strengths & Weaknesses
    7.4 IBio Inc.
        7.4.1 IBio Inc. Details
        7.4.2 IBio Inc. Major Business
        7.4.3 IBio Inc. Hereditary Angioedema Drug Product and Services
        7.4.4 IBio Inc. Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 IBio Inc. Recent Developments/Updates
        7.4.6 IBio Inc. Competitive Strengths & Weaknesses
    7.5 BioCryst Pharmaceuticals, Inc.
        7.5.1 BioCryst Pharmaceuticals, Inc. Details
        7.5.2 BioCryst Pharmaceuticals, Inc. Major Business
        7.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
        7.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 BioCryst Pharmaceuticals, Inc. Recent Developments/Updates
        7.5.6 BioCryst Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
    7.6 Ionis Pharmaceuticals, Inc.
        7.6.1 Ionis Pharmaceuticals, Inc. Details
        7.6.2 Ionis Pharmaceuticals, Inc. Major Business
        7.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
        7.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
        7.6.6 Ionis Pharmaceuticals, Inc. Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Hereditary Angioedema Drug Industry Chain
    8.2 Hereditary Angioedema Drug Upstream Analysis
        8.2.1 Hereditary Angioedema Drug Core Raw Materials
        8.2.2 Main Manufacturers of Hereditary Angioedema Drug Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Hereditary Angioedema Drug Production Mode
    8.6 Hereditary Angioedema Drug Procurement Model
    8.7 Hereditary Angioedema Drug Industry Sales Model and Sales Channels
        8.7.1 Hereditary Angioedema Drug Sales Model
        8.7.2 Hereditary Angioedema Drug Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Hereditary Angioedema Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Hereditary Angioedema Drug Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Hereditary Angioedema Drug Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Hereditary Angioedema Drug Production Value Market Share by Region (2018-2023)
    Table 5. World Hereditary Angioedema Drug Production Value Market Share by Region (2024-2029)
    Table 6. World Hereditary Angioedema Drug Production by Region (2018-2023) & (K Units)
    Table 7. World Hereditary Angioedema Drug Production by Region (2024-2029) & (K Units)
    Table 8. World Hereditary Angioedema Drug Production Market Share by Region (2018-2023)
    Table 9. World Hereditary Angioedema Drug Production Market Share by Region (2024-2029)
    Table 10. World Hereditary Angioedema Drug Average Price by Region (2018-2023) & (USD/Unit)
    Table 11. World Hereditary Angioedema Drug Average Price by Region (2024-2029) & (USD/Unit)
    Table 12. Hereditary Angioedema Drug Major Market Trends
    Table 13. World Hereditary Angioedema Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Hereditary Angioedema Drug Consumption by Region (2018-2023) & (K Units)
    Table 15. World Hereditary Angioedema Drug Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Hereditary Angioedema Drug Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Hereditary Angioedema Drug Producers in 2022
    Table 18. World Hereditary Angioedema Drug Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Hereditary Angioedema Drug Producers in 2022
    Table 20. World Hereditary Angioedema Drug Average Price by Manufacturer (2018-2023) & (USD/Unit)
    Table 21. Global Hereditary Angioedema Drug Company Evaluation Quadrant
    Table 22. World Hereditary Angioedema Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Hereditary Angioedema Drug Production Site of Key Manufacturer
    Table 24. Hereditary Angioedema Drug Market: Company Product Type Footprint
    Table 25. Hereditary Angioedema Drug Market: Company Product Application Footprint
    Table 26. Hereditary Angioedema Drug Competitive Factors
    Table 27. Hereditary Angioedema Drug New Entrant and Capacity Expansion Plans
    Table 28. Hereditary Angioedema Drug Mergers & Acquisitions Activity
    Table 29. United States VS China Hereditary Angioedema Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Hereditary Angioedema Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Hereditary Angioedema Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Hereditary Angioedema Drug Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Hereditary Angioedema Drug Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Hereditary Angioedema Drug Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Hereditary Angioedema Drug Production Market Share (2018-2023)
    Table 37. China Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Hereditary Angioedema Drug Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Hereditary Angioedema Drug Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Hereditary Angioedema Drug Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Hereditary Angioedema Drug Production Market Share (2018-2023)
    Table 42. Rest of World Based Hereditary Angioedema Drug Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Hereditary Angioedema Drug Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Hereditary Angioedema Drug Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Hereditary Angioedema Drug Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Hereditary Angioedema Drug Production Market Share (2018-2023)
    Table 47. World Hereditary Angioedema Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Hereditary Angioedema Drug Production by Type (2018-2023) & (K Units)
    Table 49. World Hereditary Angioedema Drug Production by Type (2024-2029) & (K Units)
    Table 50. World Hereditary Angioedema Drug Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Hereditary Angioedema Drug Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Hereditary Angioedema Drug Average Price by Type (2018-2023) & (USD/Unit)
    Table 53. World Hereditary Angioedema Drug Average Price by Type (2024-2029) & (USD/Unit)
    Table 54. World Hereditary Angioedema Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Hereditary Angioedema Drug Production by Application (2018-2023) & (K Units)
    Table 56. World Hereditary Angioedema Drug Production by Application (2024-2029) & (K Units)
    Table 57. World Hereditary Angioedema Drug Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Hereditary Angioedema Drug Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Hereditary Angioedema Drug Average Price by Application (2018-2023) & (USD/Unit)
    Table 60. World Hereditary Angioedema Drug Average Price by Application (2024-2029) & (USD/Unit)
    Table 61. Pharming Group NV Basic Information, Manufacturing Base and Competitors
    Table 62. Pharming Group NV Major Business
    Table 63. Pharming Group NV Hereditary Angioedema Drug Product and Services
    Table 64. Pharming Group NV Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Pharming Group NV Recent Developments/Updates
    Table 66. Pharming Group NV Competitive Strengths & Weaknesses
    Table 67. Takeda Basic Information, Manufacturing Base and Competitors
    Table 68. Takeda Major Business
    Table 69. Takeda Hereditary Angioedema Drug Product and Services
    Table 70. Takeda Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Takeda Recent Developments/Updates
    Table 72. Takeda Competitive Strengths & Weaknesses
    Table 73. CSL Limited Basic Information, Manufacturing Base and Competitors
    Table 74. CSL Limited Major Business
    Table 75. CSL Limited Hereditary Angioedema Drug Product and Services
    Table 76. CSL Limited Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. CSL Limited Recent Developments/Updates
    Table 78. CSL Limited Competitive Strengths & Weaknesses
    Table 79. IBio Inc. Basic Information, Manufacturing Base and Competitors
    Table 80. IBio Inc. Major Business
    Table 81. IBio Inc. Hereditary Angioedema Drug Product and Services
    Table 82. IBio Inc. Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. IBio Inc. Recent Developments/Updates
    Table 84. IBio Inc. Competitive Strengths & Weaknesses
    Table 85. BioCryst Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
    Table 86. BioCryst Pharmaceuticals, Inc. Major Business
    Table 87. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
    Table 88. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. BioCryst Pharmaceuticals, Inc. Recent Developments/Updates
    Table 90. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
    Table 91. Ionis Pharmaceuticals, Inc. Major Business
    Table 92. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
    Table 93. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 94. Global Key Players of Hereditary Angioedema Drug Upstream (Raw Materials)
    Table 95. Hereditary Angioedema Drug Typical Customers
    Table 96. Hereditary Angioedema Drug Typical Distributors
List of Figure
    Figure 1. Hereditary Angioedema Drug Picture
    Figure 2. World Hereditary Angioedema Drug Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Hereditary Angioedema Drug Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Hereditary Angioedema Drug Production (2018-2029) & (K Units)
    Figure 5. World Hereditary Angioedema Drug Average Price (2018-2029) & (USD/Unit)
    Figure 6. World Hereditary Angioedema Drug Production Value Market Share by Region (2018-2029)
    Figure 7. World Hereditary Angioedema Drug Production Market Share by Region (2018-2029)
    Figure 8. North America Hereditary Angioedema Drug Production (2018-2029) & (K Units)
    Figure 9. Europe Hereditary Angioedema Drug Production (2018-2029) & (K Units)
    Figure 10. China Hereditary Angioedema Drug Production (2018-2029) & (K Units)
    Figure 11. Japan Hereditary Angioedema Drug Production (2018-2029) & (K Units)
    Figure 12. Hereditary Angioedema Drug Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 15. World Hereditary Angioedema Drug Consumption Market Share by Region (2018-2029)
    Figure 16. United States Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 17. China Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 18. Europe Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 19. Japan Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 22. India Hereditary Angioedema Drug Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Hereditary Angioedema Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Hereditary Angioedema Drug Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Hereditary Angioedema Drug Markets in 2022
    Figure 26. United States VS China: Hereditary Angioedema Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Hereditary Angioedema Drug Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Hereditary Angioedema Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Hereditary Angioedema Drug Production Market Share 2022
    Figure 30. China Based Manufacturers Hereditary Angioedema Drug Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Hereditary Angioedema Drug Production Market Share 2022
    Figure 32. World Hereditary Angioedema Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Hereditary Angioedema Drug Production Value Market Share by Type in 2022
    Figure 34. C1 Esterase Inhibitor
    Figure 35. Kallikrein Inhibitor
    Figure 36. Selective Bradykinin B2 Receptor Antagonist
    Figure 37. World Hereditary Angioedema Drug Production Market Share by Type (2018-2029)
    Figure 38. World Hereditary Angioedema Drug Production Value Market Share by Type (2018-2029)
    Figure 39. World Hereditary Angioedema Drug Average Price by Type (2018-2029) & (USD/Unit)
    Figure 40. World Hereditary Angioedema Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 41. World Hereditary Angioedema Drug Production Value Market Share by Application in 2022
    Figure 42. Retail Pharmacies
    Figure 43. Hospital Pharmacies
    Figure 44. Online Pharmacies
    Figure 45. World Hereditary Angioedema Drug Production Market Share by Application (2018-2029)
    Figure 46. World Hereditary Angioedema Drug Production Value Market Share by Application (2018-2029)
    Figure 47. World Hereditary Angioedema Drug Average Price by Application (2018-2029) & (USD/Unit)
    Figure 48. Hereditary Angioedema Drug Industry Chain
    Figure 49. Hereditary Angioedema Drug Procurement Model
    Figure 50. Hereditary Angioedema Drug Sales Model
    Figure 51. Hereditary Angioedema Drug Sales Channels, Direct Sales, and Distribution
    Figure 52. Methodology
    Figure 53. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.

Related Reports

Global Hereditary Angioedema Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Hereditary Angioedema Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 26 Aug 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Hereditary Angioedema Drug market size was valued at USD 764.5 million in 2022 and is forecast to a readjusted size of USD 1188.6 million by 2029 with a CAGR of 6.5% during review period.

Global Hereditary Angioedema Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Hereditary Angioedema Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Hereditary Angioedema Drug market size was valued at USD 764.5 million in 2023 and is forecast to a readjusted size of USD 1188.6 million by 2030 with a CAGR of 6.5% during review period.

Global Hereditary Angioedema Drug Supply, Demand and Key Producers, 2024-2030

Global Hereditary Angioedema Drug Supply, Demand and Key Producers, 2024-2030

date 08 Feb 2024

date Pharma & Healthcare

The global Hereditary Angioedema Drug market size is expected to reach $ 1188.6 million by 2030, rising at a market growth of 6.5% CAGR during the forecast period (2024-2030).

Product Tags

Hereditary Angioedema Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>